Oxcarbazepine (Trileptal)

A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.

Also Known As:

Networked: 981 relevant articles (124 outcomes, 215 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Marson, Anthony G: 12 articles (01/2022 - 03/2007)
2.	Lee, Sang Kun: 9 articles (01/2021 - 01/2012)
3.	D'Souza, Joseph: 9 articles (11/2006 - 05/2002)
4.	Kim, Dong Wook: 8 articles (02/2020 - 01/2012)
5.	Luszczki, Jarogniew J: 8 articles (02/2016 - 04/2003)
6.	Chu, Kon: 7 articles (01/2021 - 01/2012)
7.	Beydoun, Ahmad: 7 articles (12/2020 - 01/2002)
8.	Cansu, Ali: 7 articles (01/2015 - 11/2006)
9.	Czuczwar, Stanislaw J: 7 articles (11/2013 - 04/2003)
10.	Kanner, Andres M: 6 articles (01/2022 - 05/2004)

Related Diseases

1.	Seizures (Absence Seizure) 09/01/2006 - "Overall, 70% experienced a significant reduction in seizures, and 50% became seizure-free while receiving oxcarbazepine. " 11/01/2007 - "Seizures improved within 4 days of oxcarbazepine initiation in six children, whereas two children required higher doses. " 01/01/2009 - "The oxcarbazepine doses of 1,200 mg (RR 17.59; 95% CI 2.37 to 130.35) and 2,400 mg (RR 25.41; 95% CI 6.26 to 103.10) were effective for keeping patients probably free from seizures, but the dose of 600 mg was not. " 11/01/2006 - "Patients with partial seizures who switched to oxcarbazepine monotherapy showed statistically significant, clinically relevant improvements in QOL." 01/01/2001 - "Furthermore, oxcarbazepine 2400 mg/day as monotherapy has also proved effective in the treatment of refractory partial seizures in adult patients. "
2.	Epilepsy (Aura) 10/01/2017 - "The aim of the study is to investigate the effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on plasma oxcarbazepine (OXC) concentrations and therapeutic efficacy in Han Chinese patients with epilepsy. " 10/01/2017 - "Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy." 11/01/1997 - "Oxcarbazepine appears to be an effective and well-tolerated drug for localization-related early childhood epilepsy. " 01/01/2023 - "This study aimed to determine the effects of oxcarbazepine (OXC) on the language function of patients with pediatric epilepsy. " 10/01/2022 - "This study aimed to investigate the factors affecting the plasma concentration of monohydroxylated derivative (MHD) of oxcarbazepine (OXC) in children with epilepsy. "
3.	Partial Epilepsies (Epilepsy, Partial) 05/01/2007 - "This study prospectively examined whether continued add-on treatment with oxcarbazepine (OXC) is associated with quantitative improvement in mood and anxiety symptoms in adult patients with partial epilepsy. " 01/01/2003 - "As a result, we found oxcarbazepine safe and effective in children with either generalized or partial epilepsy." 07/01/2015 - "The objective of this study was to explore the efficacy of low dose of oxcarbazepine (OXC) in adult patients with newly diagnosed partial epilepsy in an actual clinical setting. " 07/01/2015 - "Efficacy of low to moderate doses of oxcarbazepine in adult patients with newly diagnosed partial epilepsy." 06/27/2000 - "To evaluate the safety and efficacy of oxcarbazepine (OXC) 2,400 mg/day versus OXC 300 mg/day monotherapy in patients with medically refractory partial epilepsy. "
4.	Pain (Aches) 10/01/2005 - "His pain responded dramatically to the addition of oxcarbazepine, with rapid improvement in his symptoms and functional status. " 05/01/2016 - "Oxcarbazepine was significantly more effective for patients without evoked pain than in those with it for electrical, burning, and pricking pain. " 11/01/2014 - "In the total sample, oxcarbazepine relieved pain of 0.7 points (on a numeric rating scale 0-10; 95% confidence interval [CI] 0.4-1.4) more than placebo (P=0.015) and there was a significant interaction between treatment and phenotype of 0.7 (95% CI 0.01-1.4, P=0.047). " 12/02/2017 - "We searched the US National Institutes of Health (NIH) databases and the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing trials in January 2017, and we wrote to the companies who make oxcarbazepine and to pain experts requesting additional information. " 03/28/2013 - "We also searched the National Institutes of Health (NIH) databases and the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing trials, and wrote to the companies who make oxcarbazepine and to pain experts asking for additional information. "
5.	Trigeminal Neuralgia (Tic Douloureux) 04/01/1989 - "It is concluded that oxcarbazepine has potent antineuralgic properties in the absence of significant side effects and therefore may be useful in the management of intractable trigeminal neuralgia." 02/01/2002 - "This study therefore aimed to assess long-term outcome in patients with intractable trigeminal neuralgia treated with oxcarbazepine and later with surgery. " 03/06/2020 - "Herein, we report a case of oxcarbazepine-induced lower leg weakness in a patient with trigeminal neuralgia and summarize the diagnosis, treatment, and changes of clinical symptoms. " 03/06/2020 - "Oxcarbazepine for trigeminal neuralgia may induce lower extremity weakness: A case report." 02/01/2002 - "Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia."

Related Drugs and Biologics

1.	Carbamazepine (Tegretol)
2.	Topiramate (Topamax)
3.	Lamotrigine (Lamictal)
4.	Gabapentin (Neurontin)
5.	Anticonvulsants (Antiepileptic Drugs)
6.	Valproic Acid (Depakote)
7.	Levetiracetam (Keppra)
8.	Phenytoin (Dilantin)
9.	Zonisamide (Zonegran)
10.	Tiagabine (Gabitril)

Related Therapies and Procedures

1.	Therapeutics
2.	Vagus Nerve Stimulation
3.	Relaxation Therapy (Relaxation Technique)
4.	Psychology Biofeedback (Biofeedback)
5.	Aftercare (After-Treatment)